founders, Board of directors 

& Management

Founded by scientists who are driven to find treatments for rare neuromuscular diseases our research, drug programs and commercial efforts are all guided by science & the practice of evidence based translational development of our therapeutic strategies. 

Our goal is to develop the worlds first gene therapy to treat FSHD using novel patented CRISPRi technology.

There is currently no therapeutic treatment or cure for FSHD.

 

takako-jones.jpg

CSO, Founder, Board Director

Dr. T. Jones is an Associate Professor of Pharmacology at the University of Nevada, Reno School of Medicine  

charis-himeda.jpg

CSO, Founder, Board Director

Dr. Himeda is an Associate Professor of Pharmacology at the University of Nevada, Reno School of Medicine

I'm a paragraph. Click here to add your own text and edit me. It's easy.

Pete%20Ratcliffe%20B%26W_edited.jpg

Executive Chairman, President, Founder, Board Director

 Pete has 23 years commercial, operations, management & advisory experience in global strategic consultancy roles across Europe, US, Asia & Australia

Carly Baum.jpg

Carly is a Certified Public Accountant with over 10 years of industry experience. She spent 7 years in public accounting, and most recently has been an accounting consultant for start ups in Silicon Valley

Sue%2520Phenix_edited_edited.jpg

Scientific Advisor Pharmaceutical Development & CMC

Susan holds a PhD in Chemical Engineering from MIT and has over 19 years of industrial experience in pharmaceutical development at Pfizer and Genetics Institute/Wyeth BioPharma

Carly Baum.jpg

CSO, Founder, Board Director

Dr. Himeda is an Associate Professor of Pharmacology at the University of Nevada, Reno School of Medicine